|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Concert_Pharmaceuticals
gptkb:Semma_Therapeutics
gptkb:Exonics_Therapeutics
gptkb:Apexian_Pharmaceuticals
|
|
gptkbp:awards
|
Best Places to Work
|
|
gptkbp:ceo
|
gptkb:Reshma_Kewalramani
|
|
gptkbp:clinical_trial
|
ongoing
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaborations
|
gptkb:Vertex_Foundation
|
|
gptkbp:community_engagement
|
gptkb:healthcare_professionals
educational initiatives
patient advocacy
|
|
gptkbp:employees
|
over 3,000
|
|
gptkbp:focus
|
gptkb:cystic_fibrosis
|
|
gptkbp:founded
|
gptkb:1989
|
|
gptkbp:headquarters
|
Cambridge, Massachusetts, USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vertex Pharmaceuticals (Australia) Pty Ltd.
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:investment
|
gptkb:infrastructure
gptkb:technology
R& D
|
|
gptkbp:location
|
gptkb:Australia
|
|
gptkbp:market
|
global
|
|
gptkbp:partnerships
|
academic institutions
biopharmaceutical companies
|
|
gptkbp:philanthropy
|
cystic fibrosis research
|
|
gptkbp:products
|
gptkb:Kalydeco
gptkb:Orkambi
gptkb:Symdeko
gptkb:Trikafta
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:research
|
drug development
|
|
gptkbp:research_areas
|
gptkb:Cell
small molecules
gene editing
protein engineering
|
|
gptkbp:research_focus
|
genetic diseases
|
|
gptkbp:subsidiary
|
gptkb:Vertex_Pharmaceuticals_Incorporated
|
|
gptkbp:sustainability_efforts
|
gptkb:supply_chain_management
energy efficiency
environmental responsibility
|
|
gptkbp:type
|
private limited company
|
|
gptkbp:website
|
www.vrtx.com
|
|
gptkbp:bfsParent
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
4
|